Clinical Trial Update: A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating MM-141 in combination with nab-paclitaxel and gemcitabine in frontline metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• MM-141
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED